




RealRate

PHARMACEUTICAL 2017

ImmunoGen Inc.
Rank 160 of 313

immunogen



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of ImmunoGen Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ImmunoGen Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 67% points. The greatest weakness of ImmunoGen Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 52% points.

The company's Economic Capital Ratio, given in the ranking table, is -194%, being 222% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	254,780
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	61,439
Liabilities, Non-Current	4,192
Other Assets	9,601
Other Compr. Net Income	-19,826
Other Expenses	0
Other Liabilities	303,758
Other Net Income	0
Property and Equipment	22,704
Research and Development	148,077
Revenues	60,002
Selling, General and Administrative Expense	36,916

Output Variable	Value in 1000 USD
Assets	287,085
Liabilities	369,389
Expenses	184,993
Stockholders Equity	-82,304
Net Income	-124,991
Comprehensive Net Income	-134,904
Economic Capital Ratio	-194%